LEXINGTON, Mass.--(BUSINESS WIRE)--SynapDx Corporation today announced that founder and CEO Stanley Lapidus was inducted to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This honor recognizes Lapidus’ pioneering contributions to the field of biomedical engineering.
In 2010, Lapidus founded SynapDx to develop a novel blood test to enable the earlier detection of autism. In the U.S., the average age of diagnosis for autism spectrum disorders (ASD) is 4.5 years. However, beneficial therapies and interventions can begin at much younger ages. The SynapDx test is designed to detect patterns of gene expression to help pediatricians identify children at risk of ASD earlier than they do today.
Previously, Lapidus focused on the early detection of cancers. In 1987, he launched Cytyc Corporation where he invented the ThinPrep® Pap Test, a technology that transformed cervical cancer screening. Lapidus also founded Exact Sciences Corporation where his team developed a non-invasive, DNA-based screening test for colorectal cancer.
Lapidus has more than 30 patents and holds academic appointments at the Massachusetts Institute of Technology and Tufts University.
Founded in 1991, AIMBE is a non-profit organization whose mission is to be an authoritative voice and advocate for the value of medical and biological engineering to society. Lapidus was inducted to the College of Fellows at a ceremony at the National Academy of Sciences during AIMBE’s Annual Meeting in Washington, DC, on March 24, 2014.
About SynapDx Corp.
SynapDx is a private company developing next generation laboratory testing services for the early detection of autism spectrum disorders (ASDs). SynapDx’s investors include, General Catalyst Partners, North Bridge Venture Partners, Google Ventures, LabCorp, The Kraft Group, Foundation Medical Partners, Casdin Capital and Windham Venture Partners. SynapDx was founded in 2010 and is based in Lexington, Mass.
ThinPrep is a registered trademark of Hologic Inc.